---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-058973"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T04:58:20.790641+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health to discuss initial crofelemer POC results for MVID and SBS-IF on April 30 webcast

## Summary
- Data presented April 26 at ELITE PED-GI Congress by Dr. Mohamad Miqdady.
- No approved drug treatments for MVID, an ultrarare pediatric disease.
- Webcast on April 30, 2025 at 8:30 AM ET; includes KOL commentary.
- Ongoing POC IITs (3) and Phase 2 studies (2) for crofelemer in MVID and SBS-IF.
- Possible expedited regulatory pathways for crofelemer in MVID discussed.

## SEC filing metadata
- accession: 0000950170-25-058973
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000095017025058973/0000950170-25-058973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000095017025058973/jagx-20250428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-058973
- JSON: https://secwatch.observer/filing/0000950170-25-058973.json
- Plain text: https://secwatch.observer/filing/0000950170-25-058973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.